Hongene Biotech provides end-to-end services from raw materials to drug substance and fill/finish, supporting projects from preclinical to commercial stages.
Key Strengths:
- Vertical Integration: Full control from nucleosides, phosphoramidites, GalNAc, and enzymes to finished drug product.
- Proprietary Technology: Next-generation chemoenzymatic ligation platform for scalable, high-purity synthesis of complex oligonucleotides (e.g., siRNA, long sgRNA).
- Global Capacity: State-of-the-art GMP facilities with mid- and large-scale synthesizers, solvent recovery, and in-house analytics.
- Expertise: 25+ years in RNA industry, 1,600+ employees, 2,000+ SKUs of raw materials.
- Global Presence: R&D centers in San Francisco and Shanghai; sales offices in Boston, Hamburg, Tokyo, and more.
For more details, download the PDF, or visit Oligo CDMO services page.